Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 Gag (Group-specific antigen) is a polyprotein that plays a central and multifaceted role in the replication cycle of human immunodeficiency virus type 1 (HIV-1). It is essential for virion assembly, budding, release, and maturation. Initially considered merely a structural or scaffolding protein, extensive research has revealed that Gag orchestrates multiple critical steps in viral replication through its distinct domains.
Currently no approved antiretroviral drugs directly target HIV-1 Gag. Investigational inhibitors target capsid and maturation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Group-specific antigen polyprotein (Gag).